Effects of bronchodilation on biomarkers of peripheral airway inflammation in COPD

Pierachille Santus, Dejan Radovanovic, Susanna Mascetti, Alessia Pauletti, Vincenzo Valenti, Marco Mantero, Alberto Papi, Marco Contoli

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Peripheral airway inflammation and dysfunction are key elements in the pathogenesis of COPD. The exhaled alveolar fraction of nitric oxide (CANO) is an indirect biomarker of lung peripheral inflammation. We tested whether inhaled long-acting bronchodilators (LABA) can affect CANO and we evaluated correlations with lung mechanics in patients with COPD. Two-centre, randomised, double blind, crossover study including COPD patients with moderate-to-severe airflow obstruction. Following a pharmacological washout, multi-flow exhaled fraction of NO (FENO), plethysmography, lung diffusion (DLCO), single breath nitrogen washout test and dyspnoea were measured in a crossover manner at baseline and 30, 60 and 180 min following administration of salmeterol (Sal) or formoterol fumarate (FF). (ClinicalTrials.gov, number NCT01853787). Fort-five patients were enrolled (median age: 71.8 years; 84.4% males). At baseline, CANO correlated with airway resistances (r = 0.422), residual volume/total lung capacity (RV/TLC; r = 0.375), transfer factor (r= -0.463) and forced expiratory volume in 1 s (FEV1; r= -0.375, all P < 0.01). After LABA administration, we found a significant reduction of FENO that reached statistical significance at 180’; no difference was found between FF and S. Consistently, a significant reduction of CANO was documented at 60’ and 180’ compared to baseline for both FF and S (P < 0.01 and P < 0.05, respectively). Changes in CANO were correlated with changes in vital capacity (r=-44; P < 0.001) and RV/TLC (r = 0.56; P < 0.001), but not FEV1. In COPD, direct correlations were found between the levels of CANO and the magnitude of peripheral airway dysfunction. LABA reduced CANO levels. The reduction was associated with improvement in functional parameters reflecting air trapping.

Original languageEnglish
Pages (from-to)160-169
Number of pages10
JournalPharmacological Research
Volume133
DOIs
Publication statusPublished - Jul 1 2018

Fingerprint

Chronic Obstructive Pulmonary Disease
Bronchodilator Agents
Biomarkers
Inflammation
Total Lung Capacity
Transfer Factor
Lung
Airway Resistance
Residual Volume
Plethysmography
Vital Capacity
Forced Expiratory Volume
Mechanics
Double-Blind Method
Dyspnea
Cross-Over Studies
Pneumonia
Nitric Oxide
Nitrogen
Air

Keywords

  • Biomarker
  • Bronchodilator
  • COPD
  • Mechanical stress
  • Nitric oxide
  • Small airways

ASJC Scopus subject areas

  • Pharmacology

Cite this

Santus, P., Radovanovic, D., Mascetti, S., Pauletti, A., Valenti, V., Mantero, M., ... Contoli, M. (2018). Effects of bronchodilation on biomarkers of peripheral airway inflammation in COPD. Pharmacological Research, 133, 160-169. https://doi.org/10.1016/j.phrs.2018.05.010

Effects of bronchodilation on biomarkers of peripheral airway inflammation in COPD. / Santus, Pierachille; Radovanovic, Dejan; Mascetti, Susanna; Pauletti, Alessia; Valenti, Vincenzo; Mantero, Marco; Papi, Alberto; Contoli, Marco.

In: Pharmacological Research, Vol. 133, 01.07.2018, p. 160-169.

Research output: Contribution to journalArticle

Santus, P, Radovanovic, D, Mascetti, S, Pauletti, A, Valenti, V, Mantero, M, Papi, A & Contoli, M 2018, 'Effects of bronchodilation on biomarkers of peripheral airway inflammation in COPD', Pharmacological Research, vol. 133, pp. 160-169. https://doi.org/10.1016/j.phrs.2018.05.010
Santus, Pierachille ; Radovanovic, Dejan ; Mascetti, Susanna ; Pauletti, Alessia ; Valenti, Vincenzo ; Mantero, Marco ; Papi, Alberto ; Contoli, Marco. / Effects of bronchodilation on biomarkers of peripheral airway inflammation in COPD. In: Pharmacological Research. 2018 ; Vol. 133. pp. 160-169.
@article{94902f7b69b6427a81f597034f48ce7d,
title = "Effects of bronchodilation on biomarkers of peripheral airway inflammation in COPD",
abstract = "Peripheral airway inflammation and dysfunction are key elements in the pathogenesis of COPD. The exhaled alveolar fraction of nitric oxide (CANO) is an indirect biomarker of lung peripheral inflammation. We tested whether inhaled long-acting bronchodilators (LABA) can affect CANO and we evaluated correlations with lung mechanics in patients with COPD. Two-centre, randomised, double blind, crossover study including COPD patients with moderate-to-severe airflow obstruction. Following a pharmacological washout, multi-flow exhaled fraction of NO (FENO), plethysmography, lung diffusion (DLCO), single breath nitrogen washout test and dyspnoea were measured in a crossover manner at baseline and 30, 60 and 180 min following administration of salmeterol (Sal) or formoterol fumarate (FF). (ClinicalTrials.gov, number NCT01853787). Fort-five patients were enrolled (median age: 71.8 years; 84.4{\%} males). At baseline, CANO correlated with airway resistances (r = 0.422), residual volume/total lung capacity (RV/TLC; r = 0.375), transfer factor (r= -0.463) and forced expiratory volume in 1 s (FEV1; r= -0.375, all P < 0.01). After LABA administration, we found a significant reduction of FENO that reached statistical significance at 180’; no difference was found between FF and S. Consistently, a significant reduction of CANO was documented at 60’ and 180’ compared to baseline for both FF and S (P < 0.01 and P < 0.05, respectively). Changes in CANO were correlated with changes in vital capacity (r=-44; P < 0.001) and RV/TLC (r = 0.56; P < 0.001), but not FEV1. In COPD, direct correlations were found between the levels of CANO and the magnitude of peripheral airway dysfunction. LABA reduced CANO levels. The reduction was associated with improvement in functional parameters reflecting air trapping.",
keywords = "Biomarker, Bronchodilator, COPD, Mechanical stress, Nitric oxide, Small airways",
author = "Pierachille Santus and Dejan Radovanovic and Susanna Mascetti and Alessia Pauletti and Vincenzo Valenti and Marco Mantero and Alberto Papi and Marco Contoli",
year = "2018",
month = "7",
day = "1",
doi = "10.1016/j.phrs.2018.05.010",
language = "English",
volume = "133",
pages = "160--169",
journal = "Pharmacological Research",
issn = "1043-6618",
publisher = "Academic Press",

}

TY - JOUR

T1 - Effects of bronchodilation on biomarkers of peripheral airway inflammation in COPD

AU - Santus, Pierachille

AU - Radovanovic, Dejan

AU - Mascetti, Susanna

AU - Pauletti, Alessia

AU - Valenti, Vincenzo

AU - Mantero, Marco

AU - Papi, Alberto

AU - Contoli, Marco

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Peripheral airway inflammation and dysfunction are key elements in the pathogenesis of COPD. The exhaled alveolar fraction of nitric oxide (CANO) is an indirect biomarker of lung peripheral inflammation. We tested whether inhaled long-acting bronchodilators (LABA) can affect CANO and we evaluated correlations with lung mechanics in patients with COPD. Two-centre, randomised, double blind, crossover study including COPD patients with moderate-to-severe airflow obstruction. Following a pharmacological washout, multi-flow exhaled fraction of NO (FENO), plethysmography, lung diffusion (DLCO), single breath nitrogen washout test and dyspnoea were measured in a crossover manner at baseline and 30, 60 and 180 min following administration of salmeterol (Sal) or formoterol fumarate (FF). (ClinicalTrials.gov, number NCT01853787). Fort-five patients were enrolled (median age: 71.8 years; 84.4% males). At baseline, CANO correlated with airway resistances (r = 0.422), residual volume/total lung capacity (RV/TLC; r = 0.375), transfer factor (r= -0.463) and forced expiratory volume in 1 s (FEV1; r= -0.375, all P < 0.01). After LABA administration, we found a significant reduction of FENO that reached statistical significance at 180’; no difference was found between FF and S. Consistently, a significant reduction of CANO was documented at 60’ and 180’ compared to baseline for both FF and S (P < 0.01 and P < 0.05, respectively). Changes in CANO were correlated with changes in vital capacity (r=-44; P < 0.001) and RV/TLC (r = 0.56; P < 0.001), but not FEV1. In COPD, direct correlations were found between the levels of CANO and the magnitude of peripheral airway dysfunction. LABA reduced CANO levels. The reduction was associated with improvement in functional parameters reflecting air trapping.

AB - Peripheral airway inflammation and dysfunction are key elements in the pathogenesis of COPD. The exhaled alveolar fraction of nitric oxide (CANO) is an indirect biomarker of lung peripheral inflammation. We tested whether inhaled long-acting bronchodilators (LABA) can affect CANO and we evaluated correlations with lung mechanics in patients with COPD. Two-centre, randomised, double blind, crossover study including COPD patients with moderate-to-severe airflow obstruction. Following a pharmacological washout, multi-flow exhaled fraction of NO (FENO), plethysmography, lung diffusion (DLCO), single breath nitrogen washout test and dyspnoea were measured in a crossover manner at baseline and 30, 60 and 180 min following administration of salmeterol (Sal) or formoterol fumarate (FF). (ClinicalTrials.gov, number NCT01853787). Fort-five patients were enrolled (median age: 71.8 years; 84.4% males). At baseline, CANO correlated with airway resistances (r = 0.422), residual volume/total lung capacity (RV/TLC; r = 0.375), transfer factor (r= -0.463) and forced expiratory volume in 1 s (FEV1; r= -0.375, all P < 0.01). After LABA administration, we found a significant reduction of FENO that reached statistical significance at 180’; no difference was found between FF and S. Consistently, a significant reduction of CANO was documented at 60’ and 180’ compared to baseline for both FF and S (P < 0.01 and P < 0.05, respectively). Changes in CANO were correlated with changes in vital capacity (r=-44; P < 0.001) and RV/TLC (r = 0.56; P < 0.001), but not FEV1. In COPD, direct correlations were found between the levels of CANO and the magnitude of peripheral airway dysfunction. LABA reduced CANO levels. The reduction was associated with improvement in functional parameters reflecting air trapping.

KW - Biomarker

KW - Bronchodilator

KW - COPD

KW - Mechanical stress

KW - Nitric oxide

KW - Small airways

UR - http://www.scopus.com/inward/record.url?scp=85047399200&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047399200&partnerID=8YFLogxK

U2 - 10.1016/j.phrs.2018.05.010

DO - 10.1016/j.phrs.2018.05.010

M3 - Article

AN - SCOPUS:85047399200

VL - 133

SP - 160

EP - 169

JO - Pharmacological Research

JF - Pharmacological Research

SN - 1043-6618

ER -